<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846193</url>
  </required_header>
  <id_info>
    <org_study_id>GT005-01</org_study_id>
    <nct_id>NCT03846193</nct_id>
  </id_info>
  <brief_title>FocuS: First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD</brief_title>
  <official_title>FocuS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyroscope Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gyroscope Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label first in human Phase I/II multicentre study of GT005 in subjects with&#xD;
      Macular Atrophy due to AMD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety, the dose response and efficacy (anatomical and&#xD;
      functional visual outcomes) of three doses of GT005 administered as a single subretinal&#xD;
      injection in genetically defined subjects with Macular Atrophy due to Age-related Macular&#xD;
      Degeneration (AMD). Following consent, subjects will undergo a number of ophthalmic and&#xD;
      clinical assessments to determine eligibility for inclusion in the study. Once eligibility is&#xD;
      confirmed, subjects will be enrolled, receive treatment, and will be followed for 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>A dose escalation study of the safety and efficacy of a single subretinal injection of GT005 in subjects with Macular Atrophy due to AMD</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of Treatment Emergent Adverse Events /Treatment Emergent Severe Adverse Events (TEAE/TESAE)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of patients with TEAEs/TESAEs after subretinal injection of GT005</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geographic Atrophy</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline in GA size measured in mm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Drusen Volume</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline in GA size measured in mm3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular Sensitivity</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline in macular sensitivity measured in decibels (DB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular Reading Speed</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline in monocular reading speed measured in words/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vector Shedding</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline in vector titres measured in vector genome/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement factors</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline in levels of complement factors, measured in nanograms/ml</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <condition>Macular Degeneration</condition>
  <condition>Retinal Disease</condition>
  <condition>Eye Diseases</condition>
  <condition>Retinal Degeneration</condition>
  <condition>Geographic Atrophy</condition>
  <condition>Macular Atrophy</condition>
  <arm_group>
    <arm_group_label>GT005 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GT005 will be administered via subretinal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT005 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GT005 will be administered via subretinal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT005 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GT005 will be administered via subretinal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT005 Dose 1, 2 or 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GT005 will be administered via subretinal injection. This dose will be determined by dose levels determined to be tolerable in Arms 1,2 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT005 Dose 2 with Orbit Subretinal Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT005 Dose 3 with Orbit Subretinal Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT005 Dose 1, 2 or 3 with Orbit Subretinal Delivery Sysem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GT005</intervention_name>
    <description>A recombinant non-replicating adeno-associated viral (AAV) vector encoding a human complement factor</description>
    <arm_group_label>GT005 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GT005</intervention_name>
    <description>A recombinant non-replicating adeno-associated viral (AAV) vector encoding a human complement factor</description>
    <arm_group_label>GT005 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GT005</intervention_name>
    <description>A recombinant non-replicating adeno-associated viral (AAV) vector encoding a human complement factor</description>
    <arm_group_label>GT005 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GT005</intervention_name>
    <description>A recombinant non-replicating adeno-associated viral (AAV) vector encoding a human complement factor</description>
    <arm_group_label>GT005 Dose 1, 2 or 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GT005</intervention_name>
    <description>A recombinant non-replicating adeno-associated viral (AAV) vector encoding a human complement factor</description>
    <arm_group_label>GT005 Dose 2 with Orbit Subretinal Delivery System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GT005</intervention_name>
    <description>A recombinant non-replicating adeno-associated viral (AAV) vector encoding a human complement factor</description>
    <arm_group_label>GT005 Dose 3 with Orbit Subretinal Delivery System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GT005</intervention_name>
    <description>A recombinant non-replicating adeno-associated viral (AAV) vector encoding a human complement factor</description>
    <arm_group_label>GT005 Dose 1, 2 or 3 with Orbit Subretinal Delivery Sysem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Able and willing to give consent to study participation&#xD;
&#xD;
          2. Presence of Bilateral GA due to AMD on Color Fundus Photography (CFP)&#xD;
&#xD;
          3. Cohorts 1 to 3: GA lesions total size in the treatment eye must be&#xD;
&#xD;
             ≥1.25mm2 and ≤17.5mm2&#xD;
&#xD;
             Cohorts 4 to 7: GA lesions total size must be ≥1.25mm2 and ≤17.5mm2 for both eyes&#xD;
&#xD;
          4. Cohorts 1 to 3: the GA lesion in the treatment eye must reside completely within the&#xD;
             FAF fundus image&#xD;
&#xD;
             Cohorts 4 to 7: The GA lesion must reside completely within the FAF fundus image for&#xD;
             both eyes&#xD;
&#xD;
          5. Cohorts 1 to 3: BCVA of ≤50 letters (6/36 Snellen acuity equivalent or worse) using&#xD;
             ETDRS charts in the treatment eye&#xD;
&#xD;
             Cohorts 4 to 7: BCVA of ≥24 letters (6/95 and 20/320 Snellen acuity equivalent or&#xD;
             better) using ETDRS charts in both eyes&#xD;
&#xD;
          6. Aged ≥55 years&#xD;
&#xD;
          7. Able to attend all study visits and complete the study procedures&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Have evidence or history of choroidal neovascularization (CNV) in either eye&#xD;
&#xD;
          2. Presence of moderate/severe or worse non-proliferative, diabetic retinopathy in either&#xD;
             eye&#xD;
&#xD;
          3. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in either&#xD;
             eye&#xD;
&#xD;
          4. History of intraocular surgery in the study eye within 12 weeks prior to Screening&#xD;
             (Visit 1). Yttrium aluminum garnet capsulotomy is permitted if performed &gt;10 weeks&#xD;
             prior to Visit 1&#xD;
&#xD;
          5. Have clinically significant cataract that may require surgery during the study period&#xD;
             in either eye&#xD;
&#xD;
          6. Presence of moderate to severe glaucomatous optic neuropathy in either eye;&#xD;
             uncontrolled IOP despite the use of more than two topical agents; a history of&#xD;
             glaucoma-filtering or valve surgery is also excluded&#xD;
&#xD;
          7. Axial myopia of greater than -8 diopters in the either eye&#xD;
&#xD;
          8. Cohorts 5 to 7 only: presence of metallic objects or implanted stimulator devices in&#xD;
             or near the head, including cochlear implants, deep brain stimulators, vagus nerve&#xD;
             stimulators, and other implanted electrodes or stimulators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Gyroscope Therapeutics Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gyroscope Therapeutics Limited</last_name>
    <phone>+4401438532142</phone>
    <email>clinicaltrials@gyroscopetx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retina Vitreous Associates of Florida</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wolfe Eye Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalamic Consultants of Boston (OCB)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pepose Vision Institute</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid-Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Eye Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Vision Clinic</name>
      <address>
        <city>London</city>
        <zip>W1G 7LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manchester Eye Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunderland Eye Infirmary</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Age-related Macular Degeneration (Dry AMD)</keyword>
  <keyword>AMD</keyword>
  <keyword>Atrophic AMD</keyword>
  <keyword>Geographic Atrophy (GA)</keyword>
  <keyword>Dry-AMD</keyword>
  <keyword>Dry AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
    <mesh_term>Anetoderma</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

